Szerkesztő:Cincinn/ChAdOx1

A ChAdOx1 (Chimpanzee Adenovirus Oxford 1)^[1] egy szabadalmaztatott^[2] replikáció-képtelen adenovírus vektor, melyet többek között védőoltások létrehozására, génterápiás alkalmazásra és rákgyógyításra^{[m 1]} fejlesztettek ki 2012-ben az Oxfordi Egyetem kutatói.^[3] A vektort védőoltásként emberen már több alkalommal vizsgálták különféle kórokozók és betegségeik, például influenza^[4], tuberkulózis^[5], zika, chikungunya, valamint a közel-keleti légúti koronavírus, a MERS esetében. A védőoltásplatformot 2020 áprilisában kezdték tesztelni az új típusú koronavírus (SARS-CoV-2) ellen.^[6]

Megjegyzések

↑ l. szabadalom: In particular, the adenoviral vector and immunogenic compositions are provided for delivery of a transgene into a host cell, elicitation of an immune response in an animal, boosting an immune response in an animal, treating or preventing at least one disease, inducing an immune response in an animal that will break tolerance to a self antigen and gene therapy.

Hivatkozások

↑ Vaccitech Technology. vaccitech.co.uk . (Hozzáférés: 2020. április 14.) „The patented Vaccitech adenovirus vectors are known as chimpanzee adenovirus Oxford 1 and 2 (ChAdOx1 and ChAdOx2)”
↑ Simian adenovirus and hybrid adenoviral vectors (angol nyelven). USPTO Patent Full-text and Image Database . (Hozzáférés: 2020. április 14.) „In a particularly preferred embodiment of the present invention, the genome of the viral vector according to the present invention lacks the nucleotide sequences which encode the adenovirus E1 and E3 regions, and has the native E4 locus replaced with (..) coding regions from AdY25. This particularly preferred embodiment is referred to herein interchangeably as "ChAdOX1" or "AdChOX1".”
↑ Dicks, MDJ, Spencer AJ, Edwards NJ, Wadell G, Bojang K, Gilbert SC, et al. (2012). „A Novel Chimpanzee Adenovirus Vector with Low Human Seroprevalence: Improved Systems for Vector Derivation and Comparative Immunogenicity”. PLoS ONE 7 (7). (Hozzáférés: 2020. április 14.) „To this end, vector ChAdY25-E has been renamed ChAdOX1 for use in forthcoming clinical trials.”
↑ Antrobus, RD, L Coughlan, TK Berthoud, MD Dicks, AVS Hill, T Lambe and SC Gilbert (2014. 03). „Clinical Assessment of a Novel Recombinant Simian Adenovirus ChAdOx1 as a Vectored Vaccine Expressing Conserved Influenza A Antigens”. Molecular Therapy 22 (3). (Hozzáférés: 2020. április 14.) „we now report on the first clinical use of ChAdOx1, a novel replication-deficient simian adenovirus vector”
↑ M Wilkie et al (2019. 11). „A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime – MVA85A boost in healthy UK adults”. Vaccine 38 (4). (Hozzáférés: 2020. április 14.) „A ChAdOx1 85A prime – MVA85A boost is well tolerated and immunogenic in healthy UK adults.”
↑ Press release: Oxford COVID-19 vaccine programme opens for clinical trial recruitment. jenner.ac.uk , 2020. március 27. (Hozzáférés: 2020. április 14.) „The vaccine is an adenovirus vaccine vector (ChAdOx1) and was developed at Oxford’s Jenner Institute. It was chosen as the most suitable vaccine technology for a SARS-CoV-2 (COVID-19) vaccine as it can generate a strong immune response from one dose and it is not a replicating virus, so it cannot cause an ongoing infection in the vaccinated individual.”

[3] . szabadalom: In particular, the adenoviral vector and immunogenic compositions are provided for delivery of a transgene into a host cell, elicitation of an immune response in an animal, boosting an immune response in an animal, treating or preventing at least one disease, inducing an immune response in an animal that will break tolerance to a self antigen and gene therapy.

[1] Vaccitech Technology. vaccitech.co.uk . (Hozzáférés: 2020. április 14.) „The patented Vaccitech adenovirus vectors are known as chimpanzee adenovirus Oxford 1 and 2 (ChAdOx1 and ChAdOx2)”

[2] Simian adenovirus and hybrid adenoviral vectors (angol nyelven). USPTO Patent Full-text and Image Database . (Hozzáférés: 2020. április 14.) „In a particularly preferred embodiment of the present invention, the genome of the viral vector according to the present invention lacks the nucleotide sequences which encode the adenovirus E1 and E3 regions, and has the native E4 locus replaced with (..) coding regions from AdY25. This particularly preferred embodiment is referred to herein interchangeably as "ChAdOX1" or "AdChOX1".”

[4] Dicks, MDJ, Spencer AJ, Edwards NJ, Wadell G, Bojang K, Gilbert SC, et al. (2012). „A Novel Chimpanzee Adenovirus Vector with Low Human Seroprevalence: Improved Systems for Vector Derivation and Comparative Immunogenicity”. PLoS ONE 7 (7). (Hozzáférés: 2020. április 14.) „To this end, vector ChAdY25-E has been renamed ChAdOX1 for use in forthcoming clinical trials.”

[5] Antrobus, RD, L Coughlan, TK Berthoud, MD Dicks, AVS Hill, T Lambe and SC Gilbert (2014. 03). „Clinical Assessment of a Novel Recombinant Simian Adenovirus ChAdOx1 as a Vectored Vaccine Expressing Conserved Influenza A Antigens”. Molecular Therapy 22 (3). (Hozzáférés: 2020. április 14.) „we now report on the first clinical use of ChAdOx1, a novel replication-deficient simian adenovirus vector”

[6] M Wilkie et al (2019. 11). „A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime – MVA85A boost in healthy UK adults”. Vaccine 38 (4). (Hozzáférés: 2020. április 14.) „A ChAdOx1 85A prime – MVA85A boost is well tolerated and immunogenic in healthy UK adults.”

[7] Press release: Oxford COVID-19 vaccine programme opens for clinical trial recruitment. jenner.ac.uk , 2020. március 27. (Hozzáférés: 2020. április 14.) „The vaccine is an adenovirus vaccine vector (ChAdOx1) and was developed at Oxford’s Jenner Institute. It was chosen as the most suitable vaccine technology for a SARS-CoV-2 (COVID-19) vaccine as it can generate a strong immune response from one dose and it is not a replicating virus, so it cannot cause an ongoing infection in the vaccinated individual.”

[1]

[2]

[m 1]

[3]

[4]

[5]

[6]